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1. Introduction 
Atherogenic dyslipidemia includes increase in blood concentrations of LDL cholesterol, total 
cholesterol, triglycerides and decrease in high-density lipoprotein cholesterol, both of which 
are frequently associated with the development of cardiovascular diseases (CVDs) [1,2] 
.Treatment of dyslipidemia can reduce the risk of CVDs [3]. In both industrialized and non-
industrialized countries, the prevalence of dyslipidemia is increasing (4-7), therefore 
management of dyslipidemia has become a mainstay of routine clinical practice for both 
public health and clinicians. Although the benefits of lipid-lowering therapy have been 
demonstrated most conclusively, the role of diet determinants in dyslipidemia needs to be 
further considered [8]. Diet plays an important role in the concentrations of lipoprotein and 
is the primary intervention for patients with dyslipidemia. Understanding the relationships 
between dietary determinants and dyslipidemia and the effect of diet on lipoprotein 
concentrations may help to identify the dietary changes needed to reduce health risks [2]. 
Dietary changes, including reduced intakes of saturated fat and cholesterol, increased 
intakes of polyunsaturated fatty acids, fish, fruits and vegetables, and reduced energy 
intakes may have beneficial effects on lipoprotein concentrations [9-12]. One important 
aspect of diet is dietary patterns that address the effect of the diet as a whole and thus may 
provide insight beyond the effects described for single nutrients or foods [13]. The effects of 
some dietary patterns including the Mediterranean diet, the dietary stop to hypertension 
(DASH) and traditional dietary patterns, on lipoprotein particles need to be discussed [14, 
15, 16]. In addition, other aspects of diet, including herbal, phytochemical, and dietary 
supplement (plant stanols and sterols) also play important roles in the prevention and 
treatment of dyslipidemia and may improve lipoprotein concentrations [17]. We searched 
the medical literature for studies of the effects of diet and its component including 
macronutrient, dietary food groups, dietary patterns and herbal on disturbances of 
lipoprotein concentrations. The purpose of this chapter is to update current knowledge on 
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the role of the following dietary determinants in lipoprotein concentrations and 
dyslipidemia: including 1) macronutrients (total fat, saturated fatty acids, trans fatty acids, 
n-6 polyunsaturated fatty acids, n-3 polyunsaturated fatty acids, dietary cholesterol, 
carbohydrate and protein), 2) food groups (grains and cereal, fruit and vegetables, dairy 
products, nuts, beans and legumes, and meat, fish, poultry and eggs), 3) dietary patterns 
(Mediterranean diet, Dietary to Stop Hypertension, western diet and healthy diet), and 
therapeutic life style change (TLC), 4) dietary supplements, (plant stanols and sterols), 
herbal and phytochemicals.  
2. Diet and lipoprotein  
Lipoprotein concentrations are affected by both genetic and environmental factors. Among 
environmental factors such as physical activity and smoking, diet is an important 
component in preventing and improving dyslipidemia. Diet intervention is recommended 
by the National Cholesterol Education Program (NCEP) guidelines as first-line therapy for 
the management of disturbances in lipoprotein concentrations. Also the Third report of the 
NCEP recommended that if dietary therapy do not improve disturbances in lipoprotein 
concentrations, non-pharmacologic therapeutic factors such as viscous fiber and plant 
stanols and sterols should be recommended prior to advancing to drug therapy[18]. 
3. Macronutrient and lipoprotein 
3.1. Total fat 
The Nutrition Committee of the American Heart Association (AHA) emphasises on that 
diets providing up to 40% of dietary energy as primarily unsaturated fat (20% MUFA, 10% 
SFA, 10% PUFA and 1% TFA) were as heart healthy as low-fat diets (<30% of dietary 
energy) [19]. The effects of different dietary fatty acids on lipid profiles should be 
considered in the evaluation of strategies for controlling of disturbances in lipoprotein 
concentrations. Changes in dietary fat composition are clearly associated with changes in 
lipoprotein concentrations. Types of dietary fatty acids include saturated fatty acids (SFAs), 
monounsaturated fatty acid (MUFAs), polyunsaturated fatty acid (PUFAs) and dietary 
cholesterol, the effects of which on lipoprotein concentrations will be discussed.  
3.2. Dietary saturated fatty acids (SFAs) 
Among the dietary fatty acids only dietary SFAs and trans fatty acids increase LDL 
cholesterol concentrations [18]. The major sources of dietary SFAs are fast foods, processed 
foods, high-fat dairy products (whole milk, cheese, butter, ice cream, and cream), high-fat 
red meats, tropical oils such as palm oil, coconut oil, and palm kernel oil, baked products 
and mixed dishes containing dairy fats, shortening, and tropical oils. Dietary SFAs increase 
LDL and total cholesterol  concentrations, in comparison with all dietary fatty acids except 
trans fatty acids [20-21], by inhibiting LDL receptor activity and enhancing apolipoprotein 
(apo) β-containing lipoprotein production [22]. Every 1 percent increase of total energy from 
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dietary SFAs raises the serum LDL cholesterol about 2 percent. Conversely, a 1 percent 
reduction in saturated fatty acids will reduce serum cholesterol by about 2 percent [23,24]. 
The LDL cholesterol–raising effect of dietary SFAs depends on the intake of dietary 
cholesterol and PUFAs. In high intakes of dietary cholesterol, dietary SFAs decreased LDL 
receptor activity and increased plasma LDL concentrations [25]. However, in the adequate 
of dietary PUFAs (5–10% of total energy), dietary SFAs have no effect on LDL clearance [22]. 
In addition different dietary SFAs have different effects on lipoprotein concentrations [29]. 
Short chain SFAs have been shown to have a stronger LDL cholesterol raising effect, such 
that lauric acid (12:0) raised LDL cholesterol the most, followed by myristic (14:0) and 
palmitic (16:0) acids. In contrast, stearic acid (18:0), as a long chain SFA, has no effect on 
LDL and HDL cholesterol or the TC: HDL cholesterol ratio, and even lowers serum 
cholesterol [27,28]. Finally, the effects of dietary SFAs can be modulated by the foods in 
which they are contained. Cheeses may have smaller effects on LDL cholesterol 
concentrations than butter, and fermented dairy foods, such as yogurt, have been associated 
with LDL reductions [29]. Reduced intakes of dietary SFAs and cholesterol are first steps for 
the purpose of achieving the LDL cholesterol goal (<100 mg/dl). To maximize LDL 
cholesterol lowering by reducing dietary SFAs, it will be necessary to lower intakes of 
dietary SFAs approximately to <7 percent of total energy [18]. However the replacement of 
dietary SFAs with other macronutrients is important. Although replacement of dietary SFAs 
with carbohydrate decrease total, LDL, and HDL cholesterol, it also increases triglycerides 
[20]; however replacement of dietary SFAs by PUFAs decreases concentrations of total, LDL, 
and the LDL/HDL cholesterol ratio by decreasing LDL cholesterol production and 
increasing LDL clearance [30]. Although replacement of dietary SFAs with PUFAs has been 
shown to decrease HDL cholesterol, it decreases LDL cholesterol even more substantially; 
thus, the HDL:LDL ratio is increased [23] and the TC:HDL cholesterol ratio is decreased [26]. 
Replacement of 5% of total energy from SFAs with PUFAs reduces CHD risk by 42% [31]. 
Replacement of dietary SFAs with MUFAs has also been associated with improving 
lipoprotein concentrations, although this effect is slightly less than when PUFAs are the 
replacement dietary fatty acid [23]. Replacement of dietary SFAs with both MUFAs and 
carbohydrate decrease LDL cholesterol; however replacement with MUFA was associated 
with lower reductions in HDL cholesterol and lower arises in triglyceride concentrations [32].  
3.3. Trans fatty acids 
Trans fatty acids contain at least one double bond in the trans configuration [40] and were 
the most harmful macronutrient that increase disturbances in lipoprotein concentrations 
[26,33,34]. Dietary trans fatty acids, produced during the hydrogenation of either vegetable 
or fish oils (industrial TFA), are found in manufacturing products such as cookies, pastries, 
and salad dressings; trans fatty acids are also formed during anaerobic bacterial 
fermentation of unsaturated fatty acids that occurs in the rumen of polygastric animals such 
as cattle, sheep, and goats (natural trans fatty acids), and hence found in dairy products 
derived from the animals’ milk and meat [33,35]. Industrial and natural trans fatty acids 
contain similar types of these fatty acids, but in different proportions. Industrial trans fatty 
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acids contain trans isomers of oleic acid, the major ones being C18:1 trans-9 ( elaidic acid) 
and C18: 1 trans-10 [35]. Consumption of industrial trans fatty acids increases total, LDL 
cholesterol, and total to HDL cholesterol ratio and the LDL to HDL cholesterol ratio [33, 35-
37] and decrease HDL cholesterol [40]. Data on the effects of natural trans fatty acids on 
plasma lipoproteins in humans are inconsistent. An equivalent of 1% natural trans fatty 
acids of daily energy, has no significant effect on total cholesterol, LDL cholesterol, apo B, 
triglyceride concentrations but may be associated with a reduction in plasma HDL 
cholesterol concentrations [38]. However high intakes of natural trans fatty acids, but not 
low intakes, have adverse effects [39]. Therefore both natural and industrial trans fatty acids 
have detrimental effects on lipoprotein concentrations and their intakes should be limited 
[40]. The effects of trans fatty acids on lipid profiles are also variable, depending on their 
chain length; long chain trans fatty acids may have more adverse effect on lipid profiles. 
Partially hydrogenated fish oil or trans alpha-linolenic acid had more detrimental effect on 
lipoprotein compared with isocaloric amount of partially hydrogenated soy bean oil [37,41]. 
Effect of trans fatty acids on lipoprotein concentrations is a current topic of debate. 
Trans fatty acid intake increases lipoprotein a and triglycerides when substituted for dietary 
SFAs [42,43]. Issues related to the potential change in lipoprotein a levels induced by 
trans fatty acid intake and risk for disease need to be clarified. 
Dietary guidelines for American 2010 emphasize that consumption of trans fatty acids 
should be reduced as much as possible by limiting foods that contain sources of these fatty 
acids [43]. On the basis of these data, it should be attempts to substitute unhydrogenated oil 
for hydrogenated or SFAs in diet.  
3.4. Monounsaturated fatty acids 
Monounsaturated fatty acids have received increased attention as being potentially 
beneficial for their association with low rates of CHD in olive-oil consuming populations of 
the Mediterranean style diet [18]. The most common form of dietary MUFAs is oleic acid 
(18:1 n-9), which occurs in the cis form. Olive oil, canola oil, and sunflower oil are the main 
sources of dietary MUFAs. Oleic acid is an effective hypocholesterolemic factor when 
substituted for dietary SFAs. MUFA-rich oil consumption has been one of the strategies 
recommended for modulating the plasma lipid profile in humans. Diets containing high 
MUFA-rich foods reduce plasma total and LDL cholesterol levels and enrich LDL particles 
with cholesteryl oleate, a change in LDL particle composition that has been shown to confer 
atherogenicity [23, 45-48]. Also compared with diets rich in saturated fat, MUFA-rich diets 
lower apolipoprotein β concentrations along with declines in LDL cholesterol level [49,50]. 
Consumption of MUFA-rich diets also induces lower triglycerides and higher HDL 
cholesterol concentrations compared with low-fat, high-carbohydrate diets [51]. Long term 
MUFA-rich diets result in an earlier postprandial peak in plasma triglyceride and apo β-48 
concentrations [52,53]; this mechanism is not clear, however oleic acid has been shown to be 
preferentially esterified into triglycerides in the enterocyte [54], which may be result a faster 
entry rate of chylomicrons into the circulation, reflecting accelerated rates of digestion and 
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absorption or upregulation of chylomicron synthesis and secretion [55]. However MUFA-
rich diets increase clearance of plasma triglycerides compared with isocaloric SFA-rich or 
high complex carbohydrate diets and therefore decrease triglyceride concentrations 
[51,56,57]. MUFA substitution for dietary SFAs suggest an effective dietary strategy for 
improving disturbances of lipoprotein concentrations, which currently recommended in 
most national and international dietary guidelines [18]. 
3.5. N-6 Polyunsaturated fatty acids 
Dietary n-6 PUFAs such as linoleic acid (18:2) are widely found in a variety of vegetables 
and vegetables oils [58]. Conjugated linoleic acid (CLA), a group of naturally occurring fatty 
acids that are mainly present in foods from ruminant sources, is a collective term used to 
describe positional and geometric derivatives of linoleic acid containing conjugated double 
bonds [59]. 
CLA have beneficial effects on lipoprotein disturbances. CLA reduced total, LDL and VLDL 
cholesterol, especially atherogenic apolipoprotein β-rich lipoproteins and triglycerides 
concentrations [60,61]. CLA increases the excretion of sterols and consequently decreases 
serum cholesterol concentration [86]. 
3.6. N-3 Polyunsaturated fatty acids 
Dietary sources of n-3 PUFAs are limited. The shorter chain n-3 PUFAs FA, α-linolenic acid 
(ALA), is found in many plants, but the longer chains eicosapentaenoic acid  (EPA) and 
docosahexaenoic acid (DHA) are produced almost exclusively by cold water algae, which 
are, in turn, ingested by fish. Humans cannot synthesize the n-3 double bond, but they do 
have the elongase and desaturase enzymes to convert ALA to EPA and DHA, a conversion, 
which however is an inefficient process. The conversion of ALA to EPA may be further 
reduced as a result of large amounts of n-6 FA in the diet, which compete for the same 
enzymes. Some studies however have found that ALA, irrespective of n-6 PUFAs, has a 
beneficial effect of lipid profiles [63]. Mechanism of actions of the medium- and long chain n-3 
fatty acids appears to be independent. ALA exerts most of its effects by modulating 
lipoproteins, while EPA and DHA may reduce triglyceride synthesis [64]. Experts currently 
recommend the consumption of EPA and DHA, rather than ALA, to meet dietary goals for 
dietary n-3 PUFA [65]. Long-chain n-3 PUFA reduce triglyceride concentrations. An intake of 4 
g EPA and DHA per day results in a 25–30% decrease of fasting triglyceride concentrations in 
both normolipidaemic and hypertriacylglycerolaemic subjects (66). Compares EPA and DHA, 
EPA-ethyl ester shows no change in triglyceride concentrations, suggesting that DHA is the 
active agent in fish oil, that decreases triglyceride concentrations. Therefore among long chain 
n-3 PUFAs, EPA may produce favourable effects on triglyceride and HDL cholesterol 
concentrations [67,68]. The hypotriglyceridaemic effect of long chain n-3 PUFAs, mediated by 
several mechanisms such as enhanced hepatic fatty acid oxidation [69], inhibition of fatty acid 
and triglyceride synthesis, reduced assembly and secretion of VLDL triglyceride 
concentrations [70], facilitates triglyceride  rich lipoprotein removal through enhanced LPL 
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activity in plasma [71]. Significant increases in HDL have been observed after DHA 
supplementation [67,68,72,73]; it may be related to decreased cholesteryl ester transfer protein 
activity that reduces the exchange from HDL cholesterol ester and VLDL, resulting in larger, 
more cholesterol-rich HDL cholesterol particles [74,75].  
Inconsistent effects of DHA on total and LDL cholesterol levels have been shown; some 
investigators found a LDL cholesterol-raising effect [68,76] or no significant changes in total 
cholesterol or LDL cholesterol concentration [77,78]. After supplementation with n-3 Long 
chain PUFA, limited amounts of triglycerides are available for packaging into VLDL, which 
results in VLDL particles with low triglycerides that are readily converted to LDL, increases 
LDL cholesterol concentrations [79]. N-3 PUFAs could increase production of LDL via 
conversion of VLDL to LDL by increased lipolysis of VLDL and/or increased lipolytic 
activity or decreased clearance of LDL, by decreases in LDL receptor binding activity or 
reduced LDL receptor expression [80]. ALA, an n-3 polyunsaturated fatty acid found mainly 
in plant sources, including flaxseed oil, canola oil, and walnuts, is a metabolic precursor of 
DHA and EPA and any risk reduction may be mediated through conversion to these fatty 
acids; ALA cannot be synthesized by humans, and therefore, it is an essential fatty acid in 
diet [58]. Although evidence indicates that consumption of long chain n-3 PUFAs from 
seafood reduces the risk factors of cardiovascular disease, the effect of ALA intake in these 
risk factors is less well established. Daily supplementation with ALA-rich flaxseed is 
reported to reduce total cholesterol, LDL-cholesterol [81,82]. Weight of the evidence favors 
recommendations for modest dietary consumption of ALA (2 to 3 g per day) for primary 
and secondary prevention of CHD [58]. The relationship between ALA intake and CHD risk 
was seen among participants who consumed very little seafood; among men with limited 
seafood intake, each 1 g per day ALA intake was associated with 50% lower risk of CVDs; in 
contrast among subjects with some seafood intake, ALA intake was not associated with 
CHD risk. If benefits of ALA are greatest when EPA and DHA intakes are very low, the 
consumption of plant sources of n-3 fatty acids may be particularly important for CHD 
prevention among individuals who do not regularly consume fish [58].  
3.7. Dietary cholesterol 
The main source of dietary cholesterol is eggs, which contribute about one-third of the 
cholesterol in the diet; intake of dietary cholesterol has increased in recent year. Other 
sources of dietary cholesterol include animal products, dairy, meats, poultry, and shellfish 
[83]. High cholesterol intakes increase LDL cholesterol and the degree of rise varies from 
person to person. On average, the response of serum cholesterol to dietary cholesterol as 
revealed is approximately 10 mg/dL per 100 mg dietary cholesterol per 1000 kcal [84,85]. A 
recent meta-analysis showed that dietary cholesterol raises the ratio of total to HDL 
cholesterol, adversely affecting the serum cholesterol profile [86].  
3.8. Carbohydrate 
Recommendations to decrease fat and increase carbohydrate intake have come under 
scrutiny. Diets low in fat necessarily has a high proportion of carbohydrates, and high 
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carbohydrate diet increase triglycerides, reduce HDL cholesterol concentrations, and 
increase LDL cholesterol concentrations [87]. In addition to carbohydrate intake, the type of 
carbohydrate, according to glycemic index, most likely influences lipid profiles [88]. 
Glycemic index refers to the value obtained by feeding a carbohydrate load and measuring 
the level of blood glucose. Using the glycemic index, carbohydrates with a low glycemic 
index may decrease triglyceride concentrations and increase HDL cholesterol [89]. Also 
substituting low-GI foods for high-GI foods lowers triglyceride concentrations by 15 to 25% 
[138]. High-carbohydrate diets increase triglyceride concentrations, compared to high-fat 
diets [91] via enhance hepatic lipogenesis [92] and decrease the synthesis of lipoprotein 
lipase [93]. A high carbohydrate diet also increases glucose and insulin concentrations, the 
latter increasing lipogenesis, leading to increases in triglyceride concentrations, triglyceride-
enriched VLDL particles, and increases the LDL cholesterol concentrations [94]. Therefore 
reductions in dietary carbohydrate have been associated with reduced concentrations of 
LDL cholesterol [95] and increase means LDL particle size [96]. 
High carbohydrate diets (>60 percent of total energy) are associated with lipoprotein 
disturbances; reduction in the content of carbohydrate have beneficial effects on lipid 
profiles. However substitution of carbohydrate with other macronutrients is important. 
When carbohydrates are substituted for SFAs, the fall in LDL cholesterol levels equals that 
with monounsaturated fatty acids, and however, compared with MUFAs, this substitution 
frequently causes a fall in HDL cholesterol and a rise in triglycerides [23,97]. When dietary 
carbohydrate is consumed along with high-fiber diets, however, the rise in triglycerides or 
fall in HDL cholesterol has been reported to be reduced [98,99]. Addition of n-3 PUFA to 
low-fat, high-carbohydrate diets decreases the adverse effects of carbohydrate on blood 
lipids [51,100]. Also refined- and whole grains, as sources of carbohydrate, have an essential 
role in the metabolism of lipid profiles, that will be discussed in the section on food groups. 
In a relatively short period of time, dietary consumption of fructose has increased several 
fold above the amount present in natural foods, because of the use of high fructose corn 
sweeteners and sucrose in manufactured foods [101]. In human diets approximately one-
third of dietary fructose comes from fruit, vegetables, and other natural sources and two-
thirds is added to beverages and food in the diet (e.g. soft drinks, fruit-flavored drinks, 
candies, jams, syrups, and bakery products). Although there is little evidence that modest 
amounts of fructose have detrimental effects on carbohydrate and lipid metabolism, larger 
doses have been associated with numerous metabolic abnormalities, suggesting that high 
fructose consumption adversely affects health. High levels of plasma triacylglycerols are a 
well-established consequence of dietary fructose intake [101]. Numerous mechanisms have 
been suggested to explain this phenomenon [102,103], e.g. enhanced hepatic lipogenesis, 
and therefore overproduction of VLDL [102,104].  
3.9. Protein 
Plant sources of protein are predominantly legumes, dry beans, nuts, and, to a lesser extent, 
grain products and vegetables, which are low in saturated fats and cholesterol. Animal 
sources of protein include dairy products, egg whites, fish, poultry, and meats. Dietary 
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protein in general has little effect on lipoprotein profiles. However, substituting plant 
protein including wheat gluten, soy proteins for animal protein decrease serum cholesterol 
[104,105]. Advice on the use of soy foods to displace animal products is consistent with the 
AHA advisory on soy [107], which states that 50 g/d soy protein consumption reduces 
approximate 3% LDL-C with no apparent dose-response effect [108]. Maximum reduction in 
LDL cholesterol was achieved when ~50 g of soy protein when was replaced meat or dairy 
protein [109]. Soy is a complex protein with a globulin fraction to which its cholesterol-
lowering effect has been attributed; this fraction digested to peptides with inhibitory effects 
on cholesterol synthesis [110]. Isoflavones or the saponins found in soy, are also responsible 
for the cholesterol-lowering effect of soy [111,112]. Soy and other vegetable proteins also 
reduce oxidized LDL due to antioxidant activity [112,113].  
4. Dietary food groups and lipoprotein 
4.1. Grains and cereal 
Based on evidence from both population and intervention studies, the recommended intake 
of whole grains of the 2005 Dietary Guidelines for Americans, is at least three ounces per 
day [114]. The Dietary Guidelines Advisory Committee (DGAC) 2010 Report emphasizes 
fiber-rich carbohydrate foods such as whole grains and vegetables, fruits, and cooked dry 
beans and peas, it specifically recommends that half of the grains consumed be whole 
grains, hence some whole grains should replace refined grains [115]. Similar 
recommendations are made by the American Heart Association [116] and the American 
Diabetes Association [117]. Whole grains are referred to as “complex” or “high-quality” 
carbohydrates, mainly due to their dietary fiber content [118], which has a beneficial effect 
on body weight, and lipid profiles because they are usually less energy-dense and more 
satiating than refined-grain foods [119] may be due to their high fiber content. Among 
whole grains, oat and barley have an advantage over wheat and brown rice in lowering 
serum lipids [120,121,122], contain viscous fibres, including β-glucacon [118] that lower 
serum cholesterol; 3.5 g of β-glucan from oats reduces LDL-C by 5% [123,124]. β-glucan 
interferes with reabsorption of bile acids and cholesterol by binding to bile acids, leading to 
increase bile acid excretion and lowering the bile acid levels in the liver and thereby 
increasing the conversion rate of cholesterol to bile acids. A viscous fiber intake of 10–25 g/d 
is recommended by the National Cholesterol Education Program’s Adult Treatment Panel 
III as an additional diet option to decrease LDL cholesterol; an intake of 5–10 g/d lowers 
LDL-C by about 5% [126].  
4.2. Fruit and vegetables 
The 2010 Dietary Guidelines for Americans, recommend consuming sufficient amounts (5-13 
servings, depending on energy needs) and a varieties of fruits and vegetables to reduce the 
risk of developing chronic diseases [115]; fruits, vegetables, or both should be emphasized at 
each meal, being major sources of vitamins C, E, and A, beta-carotene, other vitamins, fiber, 
flavonoids, and some minerals. Snacks and desserts that contain fruits and/or vegetables can 
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be low in saturated fat, total fat, and cholesterol, and are very nutritious [18]. Fruits and 
vegetable intakes do not significantly change HDL cholesterol concentrations, but do decrease 
total and LDL cholesterol [9,127-132]. The protective effect of fruit and vegetables against 
CVDs is from their water-soluble and also viscous fibers (e.g. pectins) [133]. Viscous fiber 
increases fecal bile acid losses [134] and chenodeoxycholic acid synthesis [135].  
4.3. Dairy products 
Dairy products are important sources of protein, calcium, phosphorus, and vitamin D. The 
recommendation for intakes of dairy products is 2-3 serving per day; fat-free milk or 1 
percent fat milk, fat-free or low-fat cheese (e.g., ≤3g per 1 oz serving), 1 percent fat cottage 
cheese or imitation cheeses made from vegetable oils, and fat-free or low-fat yogurt are good 
choices. Fat-free milk and other fat-free or low-fat dairy products provide as much or more 
calcium and protein than whole milk dairy products, with little or no saturated fat [18].  
Recent studies confirm that milk products were associated with lower small dense LDL, and 
triglyceride concentrations, and higher HDL cholesterol [136]. In the CARDIA study, obese 
subjects with more frequent consumption of dairy products showed a trend towards lower 
risk of dyslipidaemia [137]. Minerals (calcium, magnesium), protein (casein and whey) and 
vitamins (riboflavin and vitamin B-12) have the hypocholesterolaemic effect of dairy 
product. The possible hypolipidaemic mechanism of calcium includes decreased intestinal 
absorption of cholesterol, bile acids, or fat [138], decreased fatty acid synthesis, increasing 
lipolysis, all of which lead to decreased triacylglycerol  stores [139]. Milk proteins (whey) 
[140] or peptides [141] may also play a role. Whey may act independently or synergistically 
with the calcium; attenuate lipogenesis, and accelerate lipolysis [142]. Dairy products 
contain SFAs that could affect the blood lipid profile. A recent meta-analysis of 21 
prospective cohort studies showed that the harmful effects of SFAs on CHD are still 
controversial [143]. An inverse association was shown between milk-specific fatty acids in 
serum cholesterol esters with serum cholesterol and apolipoprotein β levels [144]. 
Consumption of fat-free dairy products might decrease plasma cholesterol levels, while 
whole milk has neither a hypo- nor hypercholesterolaemic effect [139]. SFAs in dairy 
products can adversely influence CHD, although the effect of SFAs on CHD risk depends on 
the source of calories by which it is substituted to maintain energy balance [145]. Different 
dairy products have different effects on the lipid profiles. The LDL-C-raising effect of cheese 
was less than that of butter at comparable intakes of total fat and saturated fat [146,147]. 
Butter fat may increase total and LDL cholesterol by down-regulation of LDL removal from 
the circulation [148]. Fermented dairy products may have a favourite effect on lipid profiles. 
The protective effect of yogurt [139,149], a fermented dairy product, was shown to reduce 
absorption of cholesterol and therefore prevent dyslipidemia; it is thought to increase 
calcium bioavailability through its high acidity [149]. Fermented milk products may 
decrease cholesterol levels more than non-fermented products [149-151]. Probiotic yogurt 
decreased total cholesterol by 4% and LDL cholesterol by 5% [149]. A meta-analysis of 
fermented dairy products has shown a possible cholesterol lowering property, through the 
high content of probiotic bacteria [152]. 
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4.4. Nuts 
Although nuts are high in fat, in most nuts the predominant fats are unsaturated. Studies 
over the last decade have demonstrated favourable effects of nuts in modifying lipid risk 
factors for CHD [153]. However, their use is not yet part of standard advice for patients with 
hyperlipidemia, despite recognized health benefits for the general population. Intake of nuts 
fits well with current American Heart Association guidelines [19] to replace dietary SFAs 
with unsaturated fats and with the National Cholesterol Education Program (NCEP) 
guidelines to increase intake of dietary MUFAs [153]. Less atherogenic plasma lipid profiles 
associated with long-term consumption of nuts [154,155]. Addition of nuts to the habitual 
diet of both normocholesterolemic and hypercholesterolemic subjects results in a significant 
reduction in plasma total and LDL cholesterol, whereas HDL remains unchanged or 
increases [155-158]. One-percent reductions in LDL cholesterol would be achieved with 
daily intakes of 4-11 g of walnuts, pecans, peanuts, macadamias, and pistachios [50,155,157-
161]. There are several components in nuts i.e. high MUFA, high PUFAs : SFAs ratio, 
proteins (specially high arginin), plant sterols, fiber, and associated phenolic substances, 
which may all contribute to the cardioprotective effect of nuts [154,162]. Also replacement of 
dietary SFAs with MUFAs due to the high MUFA content of nuts and high content of 
vitamin E in nuts reduce susceptibility of LDL to oxidation, a key event in the development 
of CVDs [233]. Consumption of almonds, either as the whole nut or the oil, lower total and 
LDL cholesterol concentrations. Addition of 100 g of almonds to the diets reduces total 
cholesterol by 9-16% and LDL cholesterol by 12-19 % in hypercholesterolemic subjects [164]; 
in one study almond consumption also reduced fasting triglyceride concentrations by 14%, 
compared with baseline [165]. Macadamia is another nut that improve lipid disturbances, 
and its inclusion as part of a healthy diet favourably altered the plasma lipid profile, despite 
the nuts being high in fat; their consumption reduced plasma total and LDL cholesterol 
concentrations and increase HDL cholesterol without any change in the triglyceride 
concentrations [166]. These changes could contribute to high MUFA intake and lower intake 
of PUFA and SFA consumption of macadamia nuts. Of nuts, walnuts are unique in 
improving dyslipidemia because they are a rich source of PUFAs, especially α-linolenic acid 
and linoleic acid; 100 g of walnuts contain 65.2 g fat; mainly from PUFAs (47.2 g) including 
α-linolenic acid (9.1 g) and linoleic acid (38.1 g) [167]. In a meta-analysis, consumption of 
walnuts resulted in decrease in total and LDL cholesterol concentrations, whereas HDL 
cholesterol and triglycerides were not affected [168]. Despite favourable effects of nuts on 
dyslipidemia, the intake of nuts should fit within the calorie and fat goal [18].  
4.5. Beans and legumes 
Legumes include a variety of beans such as navy, pinto, kidney, garbanzo, lima beans and 
peas such as split green peas or lentils. The Dietary Guidelines for Americans suggest 
consuming 3 cups of legumes per week [18, 169]. Legumes are a rich source of soluble 
dietary fiber and vegetable protein and have long been known to be hypercholesterolaemic 
foods [170,171 ]. One-half cup of cooked beans or peas can provide a range of dietary fiber 
from 4.6 g in fava beans up to 9.6 g fiber in navy beans, with a half cup of chick peas 
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providing 6.2 g of total fiber, and 1.3 grams soluble dietary fiber [169]. In a meta-analysis 
both total and LDL cholesterol decreased, while HDL cholesterol did not change 
significantly, when diets uses supplemented with non-soy legumes [169]. The 
hypocholesterolaemic property of legumes is associated with the water-soluble fibre. 
Dietary fiber in legumes is not digested in the small intestine but be fermented in the colon 
and produces short chain fatty acids such as acetate, propionate and butyrate [172,173]; that 
inhibits hydroxy-3-methylglutaryl-CoA reductase, the limiting enzyme for cholesterol 
synthesis. Dietary fiber also decrease LDL cholesterol concentration by partially interrupting 
the enterohepatic circulation of bile acids via binding to bile acids in the intestines and 
preventing their re-absorption [174]. Consequently, an increase in the production of bile 
acids decreases the liver pool of cholesterol and increases uptake of serum cholesterol by the 
liver, decreasing thereby circulating cholesterol in the blood [175]. Another 
hypercholesterolemic component of legume is phytochemicals, which has been shown to 
reduce blood cholesterol levels and is present in small to moderate amounts in many types 
of legumes, such as chickpeas [176]. Dietary modification strategies that target the reduction 
of risk factors for CVDs should include an increase in legume consumption in addition to 
other strategies which have been of proven benefit [169].  
4.6. Meat, fish, poultry and eggs 
Recommendation for intakes of meat, fish and poultry are up to 5 oz per day from lean 
meats (beef, pork, and lamb), poultry, and fish [18]. To achieve NCEP dietary goals, 
individuals are often counselled to reduce the amount and frequency of red meat 
consumption because of its hypercholestromia effects [177-179]. Cholesterol raising effects of 
red meats appears to result from high contents of SFAs [177,179]. Therefore, lean red meats 
that provide small amounts of these fatty acids do not adversely influence the blood lipid 
profile, compared with lean white meats. In isoenergetic low-fat diets, lean meat, fish and, 
poultry had similar effects on blood lipid response in both hypercholesterolemic and 
normocholesterolemic subjects [178,180,181]. Data available suggest that meat protein, per 
se, is not hypercholesterolemic [177,181,182]. The blood cholesterol-raising potential of meat 
products appears to be a function of their SFA fat and cholesterol contents. Therefore, 
substituting lean for higher fat red meat should favourably influence serum total cholesterol 
and LDL-C levels. Incorporating lean beef, fish, or poultry into the AHA diet can be 
beneficial in lower disturbances of lipid profile in patients with hypercholesterolemia 
[178,183]. Therefore the hypercholesterolemic subjects known to be at high risk for CVDs, 
could be advised to include lean fish as well as lean beef or poultry without skin in an AHA 
diet to reduce their lipoprotein disturbances [184,185]; normolipidemic subjects can also 
incorporate lean fish in an AHA diet  [184], althought it is not necessary to eliminate or 
drastically reduce intake of lean red meat consumption because it is a rich source of iron, 
zinc and vitamin B12. One of the dietary recommendations in the prevention of CVDs is to 
limit egg consumption, because they have been shown to be a major source of dietary 
cholesterol (One egg contains 200 mg/cholesterol) that increases both serum total and LDL-
cholesterol concentrations [21,86,186]. Several epidemiologic studies however found no 
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relation between egg consumption and risk of coronary heart disease [187,188], may be 
because dietary cholesterol increases not only concentrations of total and LDL cholesterol 
but also concentrations of HDL cholesterol [21,186,189,190]. Egg intake has been also shown 
to promote the formation of large LDL particles, which is less atherogenic [191]. Therefore 
dietary recommendations aimed at restricting egg consumption should not be generalized 
to include all individuals [191].  
4.7. Dietary pattern 
Using single nutrients or dietary food groups have some limitations in assessing their effect 
on lipid profiles separately because nutrients and foods are consumed in combination. To 
date, dietary patterns consider how foods are consumed in combination, and are used to 
evaluate the effects of overall nutritional habits on health status. There are two dietary 
patterns that demonstrate the beneficial effect on disturbances of lipoprotein concentrations; 
there include the dietary to stop hypertension (DASH) and the Mediterranean diet. The 
DASH dietary pattern, rich in fruits, vegetables, and low-fat dairy foods, emphasizes fish, 
poultry, and whole grains, and is reduced in total fat, SFAs and cholesterol, red meat, 
sweets, and sweetened beverages [192,193]; it lowers total, LDL and HDL cholesterols, 
without any adverse effects on triglyceride concentrations [194]; all of these coupled with 
decrease in blood pressure, reduce 10-year coronary heart disease risk of approximately 12% 
[194]. The Mediterranean dietary pattern consists of: (a) daily consumption: of non refined 
cereals and products (whole grain bread, pasta, brown rice, etc), vegetables (2 – 3 servings/ 
day), fruits (6 servings/day), olive oil (as the main added lipid) and dairy products (1 – 2 
servings/day), (b) weekly consumption: of fish (4–5 servings/week), poultry (3 – 4 
servings/week), olives, pulses, and nuts (3 servings/ week), potatoes, eggs and sweets (3 – 4 
servings/week) and monthly consumption: of red meat and meat products (4 – 5 
servings/month). It is also characterized by moderate consumption of wine (1 – 2 
wineglasses/day). Mediterranean diet is a diet poor in SFAs and PUFAs but rich in MUFA 
(oleic acid) provided by the olive oil. The ratio of MUFAs : SFAs fat ratio is high > 2 [195]. 
This diet pattern is associated with reduction in total and LDL-cholesterol, and also a 
significant effect on triglycerides and VLDL concentrations, and a small positive or no effect 
on HDL-cholesterol [196-199] and improves dyslipidemia in dislipidemic patients [200]. This 
diet also includes antioxidant vitamins and phenolic compounds, and therefore reduces 
levels of circulating oxidized LDL and increases total antioxidant capacity [201]. Beside 
these two dietary patterns, other dietary pattern such as the western, and healthy dietary 
patterns affect lipoprotein profiles. The western pattern is characterized by high consumption 
of food such as refined grains, french fries, and red meats that have detrimental effects on lipid 
profiles. The healthy pattern included non-hydrogenated fat, vegetables, eggs, and fish and 
was negatively associated with lipoprotein disturbances [202-205]. In addition of dietary 
patterns, therapeutic lifestyle change is another dietary approach that ATP III recommends to 
reduce risks for CHD. This dietary approach includes the following: 1) Reduced intakes of 
dietary SFAs (<7% of total calories) and cholesterol (<200 mg/d), 2) weight reduction, 3) 
increased physical activity, and 4) therapeutic options for enhancing LDL lowering such as 
plant stanols/ sterols (2 g/d) and increased viscous (soluble) fiber (10-25 g/d) [18]. 
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5. Dietary supplement  
5.1. Plant stanols and sterols 
Dyslipidemia may be treated with dietary interventions, including the daily consumption of 
foods with added plant stanols or plant sterols. Plant sterols are isolated from soybean and 
tall pine-tree oils. Also some foods such as macadamia nuts are a rich source (1.28 mg/g 
lipid) of plant sterols. Plant sterols can be esterified to unsaturated fatty acids, creating sterol 
esters, to increase lipid solubility. Hydrogenating of sterols produces plant stanols. Plant 
stanols and sterols are available in commercial margarines. Daily consumption of 2 g plant 
stanols or plant sterols, expressed as free plant stanol or plant sterol equivalents improves 
dyslipidemia [18]. FDA confirms a daily dose of plant sterols and stanols of 2 g per day as 
safe, a dose which reduces LDL cholesterol by 10% [206], with little or no change in HDL 
cholesterol or triglyceride levels. There were no apparent added benefits at higher doses of 
palnts stanols and sterols. Plant stanols and sterols compete with absorption of dietary 
cholesterol and bile acid [8]. The consumption of plant stanols and sterols is an effective 
LDL cholesterol lowering strategy for patients who are undergoing statin therapy. The lipid-
lowering response to combined plant stanols and sterols/statin therapy target both intestinal 
and hepatic cholesterol metabolism. Consumption of plant stanols and sterols reduces 
intestinal cholesterol absorption and reduces hepatic cholesterol synthesis. Consumption of 
statins simultaneously with plant stanols and sterols inhibit hepatic cholesterol synthesis 
and therefore reduce in LDL cholesterol concentrations [8]. Plant sterols/stanols reduce 
absorption of dietary carotenoids, and decrease levels of plasma betacarotene; therefore 
increased intakes of fruits and vegetables are recommended with consumption of plant 
stanols/sterols[18]. 
5.2. Herbal 
There is a need to identify additional non-pharmacologic therapeutic options for cholesterol 
lowering. There is also a need to find products that are more practical for the consumer than 
viscous fiber and plant stanols and sterols to permit widespread adoption.  
5.2.1. Flavonoid 
Flavonoids have 2 aromatic rings that are bound by an oxygenated heterocyclic ring. On the 
basis of their chemical structure, they are divided into several subclasses: flavones, 
flavonols, flavanones, flavan-3-ols, anthocyanins and isoflavones. Flavones and flavonols 
are found in leaf vegetables and onion. Flavanones are mainly found in grapefruits and 
citrus fruits. Tea and cocoa are the richest sources of flavan-3-ols. Soy and soy products such 
as tofu, and miso are the main sources of isoflavones [207,208]. Although increased 
resistance of LDL to oxidation was observed after treatment with various synthetic 
pharmaceutical agents, an effort is made to identify natural food products which can offer 
antioxidant defense against LDL oxidation. Polyphenolic flavonoids are powerful 
antioxidants and their antioxidative capacity is related to their chemical structure [209]. 
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Incubation of LDL with flavonoids protects the lipoprotein against oxidation [210]. Certain 
flavonoids such as querectin could have a potentially protective role in suppression of LDL 
oxidation, regardless of the effect of antioxidant vitamins [211] via scavenging radicals and 
reduce total and LDL cholesterol concentrations, by reducing the hepatic lipogenesis [212]. 
5.2.2. Tea 
The effect of tea on lipid profiles is uncertain. Although some studies have found no lipid-
lowering effects from green or black tea consumption, most showed hypolipidemic effects 
for tea [213-218]. The association between tea drinking and lipid profile concentrations was 
linear for up to 10 cups per day, beyond which the association disappeared [219]. Daily 
consumption of 10 cups of green tea was associated with a reduction of approximately 2% in 
serum total cholesterol [219]. Tea also is a major source of flavonoids, the predominant ones 
in green tea being catechins. Theaflavins are polyphenol pigments present in black tea, 
formed from the polymerization of catechins during fermentation of green tea [220]. 
Catechins reduce intestinal cholesterol absorption [221], reduce hepatic cholesterol content 
[222] and increase fecal excretion of total fatty acids, neutral sterols, and acidic sterols [223] 
and up-regulate the LDL receptor in liver cells [224]. Polyphenol in black tea also increases 
fecal excretion of total lipids and cholesterol [225]. 
5.2.3. Chocolate 
The beneficial effects of chocolate on healthy humans have been widely addressed in recent 
years. Supplementation of cocoa products affects lipid profiles in subjects with 
cardiovascular-related diseases such as hypercholesterolemia, glucose intolerance, and 
hypertension as well as healthy individuals [226-228]. Consumption of cocoa and dark 
chocolate increase the concentration of HDL cholesterol [229] and plasma antioxidant 
capacity, decrease the formation of lipid oxidation products, and inhibit the oxidation of 
LDL [230]. In a meta-analysis study, cocoa was associated with small decreases in total and 
LDL cholesterol, but not HDL cholesterol concentrations [231]. Cocoa products contain more 
polyphenols than teas. A particular group of flavonoids, namely, the flavan-3-ols was found 
in chocolate (flavanols) [232]. Moderate consumption of cocoa or dark chocolate, have 
potential health benefits [231], however, a high dose of polyphenols has been shown to exert 
cytotoxic effects on liver cells [233] and higher polyphenol supplementation may counteract 
its beneficial biological effects on lipid metabolism [234]. 
5.2.4. Fenugreek  
Fenugreek (Trigonella foenum-graecum), an annual medicinal plant of the Fabaceae family 
is well documented for its pharmacological properties. Fenugreek seeds have been 
historically used for the treatment of various chronic diseases such as diabetes, 
dyslipidemia, and obesity [235,236 ]. The seeds of Fenugreek contain many nutrients 
including protein, carbohydrates, fat, vitamin, and minerals, fiber, saponins, choline and 
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trigonelline, polyphenolic flavonoids, steroid saponins,  polysaccharides mainly 
galactomannans and 4-hydroxyisoleucine [237,239], the fiber and saponin components of the 
seeds have been shown to have hypocholesterolemic effect [240], and the beneficial effect of 
raw fenugreek seeds on elevated serum cholesterol levels has been well established [241]. 
Raw fenugreek seeds reduce serum total cholesterol, LDL cholesterol, VLDL cholesterol and 
triglyceride concentrations, without altering the HDL fraction [242]; intakes of 20–25 g in 
three divided doses yielded maximum benefit in the control of cholesterol concentrations 
[243]. Its use as a dietary adjunct however is limited because of its bitterness. Soaking and 
washing of fenugreek seeds in water overnight removes the bitterness to a certain extent 
and makes then edible [243,244]. 
5.2.5. Ginseng 
The beneficial metabolic effects of ginseng on lipid profiles as a hypolipidemic agent were 
reported over 20 years ago [245-247]. Ginseng leads to reduction of cholesterol and 
triglyceride concentrations in liver and serum. Administration of red ginseng powder and 
extract reduces plasma total cholesterol, triglycerides, FFA, and increased HDL-C [248,249 ]. 
Ginseng saponins may decrease blood cholesterol concentrations by increasing cholesterol 
excretion through bile acid formation [249,250]. Ginsenoside, one of active components of 
ginseng saponins, may accelerate serum cholesterol turnover by increased cholesterol 
degradation and excretion in the feaces notwithstanding increased hepatic cholesterogenesis 
[250,251]. Ginseng saponins as ginsenosides increase LDL receptors by promoting the 
synthesis of LDL receptors[252].  
5.2.6. Ginger 
Ginger has been listed in the ‘‘Generally Recognized as Safe’’ by FDA [338]; fresh ginger 
rhizome contains polyphenolic compounds such as gingerols; zingerone, which is the major 
active component and gingerol, is one of the most abundant constituents in the gingerol 
series and also responsible for its characteristic pungent taste [253,254]. Ginger oleo-resin 
and dried ginger rhizome reduce hypercholesterolaemia. The speculated mechanism for 
these compounds is by disrupting cholesterol absorption from the gastro-intestinal tract 
[255], which may be due to the presence of niacin in ginger, and it causes increased 
clearance of VLDL, lowers triglyceride levels, increases hepatic uptake of LDL and 
inhibition of cholesterogenesis [256]. Ginger powder significantly reduces the extent of lipid 
peroxidation and improves plasma antioxidant capacity, which decreases plasma-free 
radicals [257]. Moreover, polyphenolic flavonoids present in ginger may prevent coronary 
artery disease by reducing plasma cholesterol levels or by inhibiting LDL oxidation [258]. 
Reduction in serum triglycerides is dose dependent; doses of 200 and 400 mg/kg of ginger 
are more effective as antihypercholesterolaemics than atorvastatin when given for 4 weeks 
and are equivalent to it when given for shorter period under the same conditions of diet and 
life style for the treatment of the same pathologic condition. The triglyceride lowering effect 
of ginger may be due to ginger’s ability to enhance lipase activity [255].  
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5.2.7. Licorice 
Licorice root, derived from the plant Glycyrrhiza glabra is used widely in Asia as a 
sweetener or a spice, contains flavonoids from the flavan and chalcone subclasses, and has a 
antioxidative properties [259]. Licorice-derived glabridin binds to the LDL particle and 
protects it from oxidation by its capacity to scavenge free radicals and its property to reduce 
the LDL aggregation [260,261].  
6. Conclusion 
Diet therapy is the initial recommended intervention for prevention of and managing 
disturbances of lipoprotein concentrations, prior to advancing to drug therapy. Further 
research on the association between dietary components and lipoprotein disturbances is 
recommended. 
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